Sunpharma vs Apollohosp Q3 FY25

Sun Pharma delivered a solid Q3 FY25 with consolidated sales of INR 13,437 crore, up 10.5% YoY, driven by strong India (13.8% growth) and emerging markets (10.1% growth). EBITDA margin expanded 120 bps YoY to 29.3%, aided by lower material costs and milestone income. Adjusted PAT grew 24.1% YoY to INR 3,220 crore. Specialty sales rose 24.8% to $370M, with balanced contribution from US and ex-US markets. India business gained 40 bps market share to 8.2%, led by volume and new launches. R&D spend was lower than guided at 6.3% of sales due to clinical trial delays; FY25 R&D guidance trimmed to <7%. Management remains focused on specialty pipeline, including Leqselvi (litigation oral arguments in April) and Antibe acquisition. Key risk: potential US tariff policy changes and FDA compliance issues at Halol facility could impact generics recovery.

Guidance read

FY25 R&D spend to be less than 7% of sales: Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales. Leqselvi launch timeline dependent on litigation outcome: Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026. Specialty sales growth to normalize after Q3 inventory build: Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.

Risk read

Key risks include US Tariff and Policy Uncertainty — Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.; FDA Compliance at Halol Facility — Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.; Leqselvi Litigation Risk — If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.; Clinical Trial Delays Impacting R&D Pipeline — Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Apollo Hospitals delivered a strong Q3 FY25 with consolidated revenue of INR 5,527 crore (+14% YoY) and EBITDA of INR 762 crore (+24% YoY). PAT surged 52% YoY to INR 372 crore, driven by mid-teens growth across all segments and margin expansion in healthcare services (24.1% EBITDA margin). The hospital business saw 13% revenue growth, with high-margin CONGO specialties (cardiac, oncology, neuro, gastro, ortho) growing at 10.35% volume, offsetting a 1.5% revenue drag from Bangladesh patient decline. Apollo HealthCo (pharmacy & digital) grew 15% YoY, with digital losses narrowing. Management guided for calibrated bed additions (1,737 beds over FY26-27) with minimal margin impact (~100 bps), and expects Apollo 24/7 to break even by Q2/Q3 FY26. Key risk: slower-than-expected recovery in Bangladesh patient inflows and competitive pressure in digital pharmacy.

Guidance read

Apollo 24/7 break-even by Q2/Q3 FY26: Digital platform expected to achieve EBITDA break-even by end of Q2 or Q3 of next fiscal year, with GMV target of INR 900-1,000 crore. Hospital margin trajectory ~24% despite new beds: Healthcare services EBITDA margin expected to remain around 24% next year, with new bed openings impacting margins by no more than 100 bps. New hospital commissioning schedule: Pune and Kolkata hospitals to open in H1 FY26; Hyderabad and Gurugram by end of FY26; 50% of 1,737 beds operational in FY26, rest in FY27. HealthCo revenue target of INR 25,000 crore by FY27: Apollo HealthCo (including Keimed) targets INR 25,000 crore revenue and 7-8% EBITDA margin by FY27.

Risk read

Key risks include Bangladesh patient decline persists — Bangladesh patient footfall dropped, causing 1.5% revenue impact; management is exploring other international markets but recovery timeline uncertain.; Digital pharmacy competitive pressure — Analyst raised concerns about high ESOP costs and competition from startups; management acknowledged but defended ESOP as retention tool.; New bed ramp-up risk — Large capacity addition (1,737 beds) could pressure margins if occupancy ramps slower than expected; management expects 100 bps margin impact..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.